Danaher (NYSE:DHR) Releases Quarterly Earnings Results

Danaher (NYSE:DHR) posted its quarterly earnings data on Wednesday. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14, RTT News reports. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period last year, the firm earned $2.09 earnings per share.

Danaher Price Performance

NYSE DHR traded up $2.85 on Friday, reaching $225.93. 505,157 shares of the stock traded hands, compared to its average volume of 3,466,284. Danaher has a 12 month low of $221.34 and a 12 month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm’s fifty day simple moving average is $235.66 and its 200 day simple moving average is $253.24. The company has a market cap of $163.18 billion, a price-to-earnings ratio of 42.79, a P/E/G ratio of 4.22 and a beta of 0.83.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s payout ratio is 20.45%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on DHR shares. Robert W. Baird reduced their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday. Barclays reduced their target price on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday. TD Cowen upped their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. JPMorgan Chase & Co. reduced their price objective on Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday. Finally, Guggenheim assumed coverage on shares of Danaher in a research report on Thursday, December 19th. They issued a “buy” rating and a $275.00 price objective for the company. Six analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $278.00.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.